Selective inhibition of mitochondrial sodium-calcium exchanger protects striatal neurons from α-synuclein plus rotenone induced toxicity

Guendalina Bastioli1,2, Silvia Piccirillo3, Pasqualina Castaldo2, Simona Magi3, Alessandro Tozzi2,4, Salvatore Amoroso3 and Paolo Calabresi1,2

Abstract
Progressive accumulation of α-synuclein (α-syn) and exposure to environmental toxins are risk factors that may both concur to Parkinson’s disease (PD) pathogenesis. Electrophysiological recordings of field post synaptic potentials (fEPSPs) and Ca^{2+} measures in striatal brain slices and differentiated SH-SYSY cells showed that co-application of α-syn and the neurotoxic pesticide rotenone (Rot) induced Ca^{2+} dysregulation and alteration of both synaptic transmission and cell function. Interestingly, the presence of the mitochondrial NCX inhibitor CGP-37157 prevented these alterations. The specific involvement of the mitochondrial NCX was confirmed by the inability of the plasma membrane inhibitor SN-6 to counteract such phenomenon. Of note, using a siRNA approach, we found that NCX1 was the isoform specifically involved. These findings suggested that NCX1, operating on the mitochondrial membrane, may have a critical role in the maintenance of ionic Ca^{2+} homeostasis in PD and that its inhibition most likely exerts a protective effect in the toxicity induced by α-syn and Rot.

Introduction
Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder mainly characterized by the damage of neurons of basal ganglia and four cardinal motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability. These pathological features are induced by the slow and progressive death of dopaminergic neurons of the substantia nigra. The histopathology of PD is also characterized by the presence of Lewy bodies, which are mainly composed of aggregates of the α-synuclein (α-syn) protein. Accordingly, many studies showed that in PD patients the presence of α-syn is increased in the brain. Mutations and multiplication of the α-syn gene (SNCA) are associated with familial PD. Several studies have tried to understand the role of fibrillary and oligomeric forms of α-syn on neuronal damage. Conversely, only a few studies are available on the mechanisms underlying α-syn-induced synaptic dysfunction. The striatum, a subcortical nucleus receiving major excitatory inputs from the cortex and the thalamus, is a brain region particularly involved in PD. We previously demonstrated that exogenous α-syn application, applied at nanomolar concentrations, directly affects striatal neurotransmission by targeting N-methyl-D-aspartate (NMDA) receptors and reducing synaptic currents. This α-syn-triggered NMDA receptor-dependent alteration might in turn participate in intracellular spreading of α-syn, also affecting NCX1 function expressed in the striatum at the mitochondrial level.
toxins, such as pesticides, can increase the levels of α-syn11. Among these drugs, rotenone (Rot), an inhibitor of voltage-gated Ca\(^{2+}\) channels12,13. Moreover, experiments on human neuroblastoma SH-SY5Y cells reported that combined exposition to α-syn and Rot deregulates Ca\(^{2+}\) homeostasis by opening voltage-gated Ca\(^{2+}\) channels15,16. Indeed, the deregulation of Ca\(^{2+}\) homeostasis, both at cytosolic and mitochondrial levels, might contribute to the pathophysiology of neurodegenerative diseases including PD17–20. Both in in vitro and in vivo models of PD, it has been demonstrated that NCLX is an essential regulator of mitochondrial Ca\(^{2+}\) homeostasis17,18. However, several studies seem to indicate that other transporters may also play a role21,22. Among them, Na\(^{+}\)-Ca\(^{2+}\) exchanger (NCX) has recently gained much attention. NCX is a key regulator of ionic homeostasis at both the plasma membrane and mitochondrial levels, as it can facilitate Na\(^{+}\) and Ca\(^{2+}\) flow in bidirectional way23,24. NCX family encompasses three members NCX1, NCX2, and NCX3 differently expressed in the brain25,26. NCX1 is particularly expressed in the basal ganglia where it represents a key player in controlling ionic homeostasis at both plasma membrane and mitochondrial levels in the striatum20,25,26. A role of plasma membrane NCX in the pathogenesis of PD has also been suggested27. In particular, the administration of an inhibitor of plasma membrane NCX attenuated the degeneration of dopaminergic neurons in a PD model27.

The aim of the present study was to analyze the involvement of both plasma membrane and mitochondrial NCX1 in the toxicity induced by combined application of α-syn and Rot in different neuronal models. Specifically, as in vitro model we used SH-SY5Y human neuroblastoma cells differentiated with retinoic acid to a neuron-like state; as ex vivo model we used striatal slices from adult rats.

**Materials and methods**

**Animals**

For electrophysiological experiments we used 2–3-month-old male Wistar rats (Charles River, Calco, Italy). All experimental procedures were conducted in conformity with the European Directive 2010/63/EU, in accordance with protocols approved by the Animal Care and Use Committee at the University of Perugia. All efforts were made to minimize the number of animals used as well as their suffering.

**Electrophysiology**

The brain was rapidly removed and coronal corticostriatal slices (270 µm) were cut in artificial cerebrospinal fluid (aCSF) solution (in mM: 126 NaCl, 2.5 KCl, 1.2 MgCl\(_2\), 1.2 NaH\(_2\)PO\(_4\), 2.4 CaCl\(_2\), 10 glucose, and 25 NaHCO\(_3\)) using a vibratome. The slices were maintained in aCSF, bubbled with an O\(_2\) 95% and CO\(_2\) 5% gas mixture (pH = 7.4) at room temperature (RT). Single coronal slices including the cortex and the striatum were transferred to a recording chamber and submerged in a continuously flowing aCSF (33 °C; 2.5–3 ml/min) bubbled with a 95% O\(_2\)-5% CO\(_2\) gas mixture. Glutamatergic field excitatory postsynaptic potentials (fEPSPs) were evoked every 10 s by means of a bipolar electrode connected to a stimulation unit (Grass Telefactor) and located in the white matter between the cortex and the striatum to activate glutamatergic fibers. The recording borosilicate glass electrode filled with 2 mM NaCl (resistance 10–15 MΩ) was placed in the dorsolateral striatum. All drugs were dissolved in aCSF and bubbled with O\(_2\) 95% and CO\(_2\) 5% gas mixture during all the experiments. Then, 10 µM SN-629,30 or 3 µM CGP-3715731 was sent in perfusion alone for 20 min and in co-application with 0.3 µM Rot. The slices treated with 3 nM α-syn were incubated for 1 h before the application of Rot.

**Cell culture**

Human neuroblastoma cell line SH-SY5Y was obtained from American Type Culture Collection (ATCC CRL-2266). SH-SY5Y cells were cultured in 100 ml Petri dishes using Eagle’s minimum essential medium (MEM)/Nutrient Mixture Ham’s F-12 (1:1) media supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin. The cell culture medium was replaced every 2 days. The cells were maintained in a humidified incubator at 37 °C and 5% CO\(_2\).

Differentiation into neuron-like cells was achieved by treatment with 10 µM all-trans retinoic acid (RA)32,33 that was added to the cell culture medium every 3 days for 1 week prior to performing the experiments.

**Silencing of NCX1 expression**

RNA interference (RNAi) was performed as described earlier34,35 with minor modifications. Specifically, silencing of NCX1 isoform was performed according to Qia-gen manufacturer’s instruction using HiPerfect Transfection Kit (Qiagen) and FlexiTube small
interference RNA (siRNA) for NCX1 (Qiagen, Hs_SLC8A1_9), and FlexiTube siRNA for NCX3 (Qiagen Hs_SLC8A3_7). The validated irrelevant Allstars siRNA (Qiagen) was used as a negative control. Target sequences of the FlexiTube NCX1 siRNA was Hs_SLC8A1_9 (5′-CAGGGCATCTTCTAAAGACTGA-3′), and of the NCX3 siRNA sequences was Hs_SLC8A3_7 (5′-ACCA TTGTTCCTAAAGATTCA-3′). The transfection protocol was as follows: SH-SY5Y cells (200,000 cell/well) were differentiated with 10 μM RA in 6-well plates for 7 days. After differentiation protocol, SH-SY5Y cells were incubated 48 h with 2.3 ml of MEM/F-12 media containing 100 µl of MEM/F-12 (without FBS and antibiotics), 12 µl of HiPerfect Transfection Reagents, and 80 nM of siRNA oligonucleotide (each well). At 48 h after transfection, cells were subjected to specific treatments. The yield of RNA silencing was assessed by western blot analysis using specific antibody.

Analysis of mitochondrial Ca²⁺
Experimental protocol for slices
Mitochondrial Ca²⁺ levels were monitored by single-cell computer-assisted video imaging using a LSM 510 confocal system (Carl Zeiss, Milan, Italy)36. The slices were loaded with 5 µM Rhod 2-AM (Molecular Probe, Eugene, OR) in aCSF solution bubbled with O₂ 95% and CO₂ 5% gas mixture for 1 h in the dark at RT37. The slices were then washed once in aCSF solution and placed into a perfusion chamber mounted onto the stage of an inverted Zeiss Axiovert 200 microscope. Mitochondrial Ca²⁺ levels were evaluated as fluorescence increase. Bath solution was changed with a peristaltic pump and images were acquired every 5 s. Excitation light was provided by argon laser at 488 nm and the emission was time-lapsed recorded at 505–530 nm. Analysis was obtained as previously described39,40. Pharmacological modulation of plasma membrane or mitochondrial NCX was performed by exposing to 1 µM SN-6 or 3 µM CGP-37157, respectively35. Before drug application, to acquire a stable baseline, RA-differentiated SH-SY5Y cells were perfused with buffer solution for 5 min and for 25 min with buffer solution to control, and for 25 min for other drugs dissolved in buffer solution.

Antibodies
NCX1 protein was detected using a commercially available mouse monoclonal IgG antibody39 (R3F1, Swant, Bellinzona, Switzerland, dilution 1:50). To detect NCX3 protein we used a rabbit monoclonal IgG antibody (95209, Swant, Bellinzona, Switzerland, dilution 1:200)31,35.

Immucytchemistry
Differentiated SH-SY5Y cells were loaded with MitoTracker 300 nM (MitoTracker Red CMXRos M7512 Invitrogen)31 for 30 min at 37 °C and then fixed with PBS and 3.7% formaldehyde for 30 min at RT and then permeabilized with PBS-Triton X-100 for 5 min at RT. After permeabilization, cells were incubated with NCX1 or NCX3 primary antibody for 20 min. Immunoreactions were revealed by incubation with secondary antibody conjugated (Alexa Anti-Mouse 488, Alexa Anti-Rabbit 488 respectively).

Drugs and chemicals
2-[(4-Nitrophenyl) methoxy] phenyl] methyl]-4-thiazolidinecarboxylic acid ethyl ester (SN-6) and the mitochondrial NCX inhibitor 7-chloro-3,5-dihydro-5-phenyl-1H-4,1-benzothiazepine-2-on (CGP-37157) were obtained from Tocris. Human recombinant α-syn and Rot were purchased from Sigma.

Data analysis
Data analysis was performed off-line using Clampfit 10 (Molecular Devices) and GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA). Values given in the"
and figures are mean ± S.E.M., where n represents the number of slices used for each electrophysiological recording. Changes in the evoked fEPSP amplitudes induced by drugs were expressed as a percentage of the baseline, the latter representing the normalized fEPSP mean amplitude acquired during a stable period (10 min) before drug administration. Two-way analysis of variance (ANOVA), followed by Bonferroni's post hoc test, were used for statistical analysis. The significance level was established at P < 0.05.

Ca^{2+} levels data were expressed as mean ± S.E.M. The n represents the number of independent experiments and 100–200 cells were recorded in each different session. Values less than 0.05 were considered to be significant. Differences among means were assessed by one-way ANOVA followed by Dunnett’s post hoc test.

Results
Effect of pharmacological inhibition of NCX1 on electrophysiological recordings of striatal fEPSP amplitude

It has been previously shown that α-syn and Rot impact neuronal cell viability, in particular they reduce mitochondrial complex I activity causing changes of Ca^{2+} levels. In order to test whether α-syn affected per se the basal synaptic transmission, we recorded the fEPSP for 40 min in the presence of 3 nM α-syn in control striatal slices. In this condition we found no effect of α-syn on the fEPSP (Fig. 1a). Afterwards, we studied the effect of α-syn plus Rot. We recorded striatal fEPSPs in control slices and then in slices exposed for 1 h to α-syn. After acquiring a stable baseline for 10 min, 0.3 µM Rot was applied for further 40 min. We found that the fEPSP amplitude, in slices maintained in control medium (aCSF), was reduced by 30% with respect to baseline values (before Rot exposure), while the fEPSP amplitude of slices pretreated with 3 nM α-syn was reduced by 60% compared to baseline. Thus, the incubation of the slices with α-syn for 1 h significantly increased the detrimental effect of Rot on the fEPSP amplitude with respect to the effect of Rot in control slices (Fig. 1b) (P < 0.0001).

Since NCX plays a critical role in Ca^{2+} homeostasis, we hypothesized that NCX1 was involved in the toxic effects exerted by α-syn plus Rot. To explore this issue, we used the plasma membrane NCX1 inhibitor SN-6 (10 µM) and the mitochondrial NCX (NCX_m) inhibitor CGP-37157 (3 µM). SN-6 affected neither the striatal response to Rot alone nor response to the combined application of Rot and α-syn (Fig. 2a) (P > 0.05), suggesting that the plasma membrane NCX1 was not involved in the toxic effects of α-syn and Rot. To investigate the role of NCX_m isoform, striatal slices were exposed to CGP-37157 for 20 min. While this drug did not affect the toxic effect induced by Rot alone, it was able to reduce the detrimental effect produced by the combined application of α-syn and Rot (P < 0.05).

Fig. 1 Effect of α-synuclein (α-syn) and rotenone (Rot) on striatal rat slices. a Time-course graph showing the field excitatory postsynaptic field potential (fEPSP) amplitude measured in striatal slices before (pre-drug) and following 3 nM α-syn (n = 5, filled symbols) or 0.3 µM Rot (n = 10, open symbols) applied for 40 min. The traces show field potentials recorded before (pre-drug) and 40 min after 3 nM α-syn or 0.3 µM Rot. b Time course of the fEPSP amplitude measured before and following 0.3 µM Rot applied for 40 min (n = 10, open symbols) and before and following 0.3 µM Rot in slices incubated for 1 h with 3 nM α-syn (n = 13, filled symbols) (two-way analysis of variance (ANOVA), group main factor, F(1, 32) = 19.79, ***P < 0.0001). The traces show field potentials recorded before and 40 min after 0.3 µM Rot in a striatal slice incubated for 1 h with 3 nM α-syn.
α-syn and Rot on the fEPSP amplitude (Fig. 2b), suggesting a critical role for NCXm in the damage induced by α-syn and Rot in our experimental model.

**Analysis of mitochondrial Ca2+ levels in striatal slices**

It has been reported that α-syn and Rot increase mitochondrial Ca2+ levels and membrane depolarization of neurons9,10,41. Thus, we analyzed the effect of α-syn and Rot alone on mitochondrial Ca2+ levels of striatal neurons obtained from striatal slices preparations (Fig. 3a). We found that neither α-syn nor Rot induced per se significant changes of mitochondrial Ca2+ levels, while combined application of these two agents significantly increased mitochondrial Ca2+ levels of 31% (Fig. 3b) (P < 0.0001). This increase was statistically significant with respect to control and to all other groups. Interestingly, incubation with CGP-37157 was able to reduce the increase of mitochondrial Ca2+ levels induced by combined application of α-syn and Rot (Fig. 3b, c) (P < 0.001).

**Analysis of mitochondrial Ca2+ levels in RA-differentiated SH-SY5Y cells**

The involvement of NCX on the increase of mitochondrial Ca2+ levels caused by the combined application of α-syn and Rot was evaluated in Rhod-2-loaded SH-SY5Y cells. We blocked plasma membrane and mitochondrial NCX1 using 1 µM SN-6 and 3 µM CGP-37157, respectively. In order to assess the role of NCX1 we used the RNAi approach to specifically silence its expression.

We found that mitochondrial Ca2+ levels significantly increased (22%) in the presence of α-syn plus Rot and this effect was statistically significant with respect to control
and all other groups (Fig. 4a, c) \( P < 0.0001 \). In line with the results obtained on fEPSP in striatal slices, SN-6 did not counteract the mitochondrial \( Ca^{2+} \) level deregulation induced by \( \alpha \)-syn plus Rot, suggesting that plasma membrane NCX1 was not involved in such response (Fig. 5). By contrast, pretreatment with CGP-37157 reduced the effect of \( \alpha \)-syn plus Rot on mitochondrial \( Ca^{2+} \) levels (Fig. 4b, c) \( P < 0.001 \).

We also used the RNAi-mediated approach to specifically silence NCX1 expression. Considering that differentiated SH-SY5Y cells express both NCX1 and NCX3 isoforms but not NCX2, the specificity of NCX1 silencing towards NCX3 expression was further verified (Fig. S1). This approach specifically targeted NCX1 isoform inducing a reduction of its mitochondrial protein level without exerting any effect on NCX3 at both plasma membrane and mitochondrial levels (Fig. S1). Notably, the reduced NCX1 expression was able to prevent the increase in mitochondrial \( Ca^{2+} \) levels induced by \( \alpha \)-syn plus Rot application (Fig. 4d, e). Overall, these findings supported the hypothesis that mitochondrial NCX1 plays an important role in the dysregulation of \( Ca^{2+} \) homeostasis induced by \( \alpha \)-syn plus Rot.

**Discussion**

The regulation of \( Ca^{2+} \) homeostasis is an important process for neuronal survival, and its dysregulation has long been recognized to play a major role in neurodegenerative diseases. In the present study, using different neuronal models (namely striatal slices and RA-differentiated SH-SY5Y cells), we showed that mitochondrial NCX1 is involved in the cell toxicity induced by the concomitant exposure to \( \alpha \)-syn and Rot. In particular, this finding is supported by three main results. Firstly, the alteration of striatal electrical activity induced by \( \alpha \)-syn and Rot is prevented by pharmacological inhibition of mitochondrial NCX with CGP-37157, but not by using the plasma membrane NCX inhibitor SN-6. Secondly, \( \alpha \)-syn and Rot increased mitochondrial \( Ca^{2+} \) levels in striatal slices through a mechanism that involved NCXm.
Fig. 4 Effect of CGP-37157 and siNCX1 on mitochondrial Ca\(^{2+}\) levels in SH-SY5Y differentiated cells exposed to α-synuclein (α-syn) and rotenone (Rot). a Representative images of SH-SY5Y differentiated cells loaded with Rhod 2-AM before (left) and after Rot+α-syn application (right). b Histogram showing mitochondrial Ca\(^{2+}\) levels expressed as Δ% fluorescence increases under resting conditions (open bars) and during 3 nM α-syn + 0.3 µM Rot applied alone or in combination with 3 µM CGP-37157 (filled bars). For each experimental group (control, CGP-37157, α-syn, α-syn+Rot, CGP-37157+α-syn+Rot), Δ% values used for the statistical analysis derived from 4 independent experiments and 100–200 cells were recorded in each different session (*P < 0.0001, α-syn+Rot vs all groups; #P < 0.001, CGP-37157+α-syn+Rot vs α-syn+Rot; CGP-37157+α-syn+Rot vs control; CGP-37157+α-syn+Rot vs α-syn). c Representative recordings of mitochondrial Ca\(^{2+}\) responses in control conditions (black line), in the presence of α-syn+Rot (green line) co-applied with 3 µM of CGP-37157 (orange line). d Histogram showing mitochondrial Ca\(^{2+}\) levels expressed as Δ% fluorescence increases in SH-SY5Y control cells, in SH-SY5Y cells treated with siNCX, in cells treated with α-syn+Rot, and in cells silenced with siNCX and α-syn+Rot. For each experimental group Δ% values used for the statistical analysis derived from 6 independent experiments and 100–200 cells were recorded in each different session (*P < 0.0001, α-syn+Rot vs all groups; #P < 0.001 siNCX α-syn+Rot vs all groups). e Representative recordings of mitochondrial Ca\(^{2+}\) responses in control conditions (black line), in the presence of α-syn+Rot (blue line), and α-syn+Rot in cells silenced with siNCX1 (cyan line).
Since CGP-37157 partially prevented this response. Finally, the silencing of NCX1 in RA-differentiated SH-SY5Y cells prevented the increase of mitochondrial Ca\(^{2+}\) levels and mimicked the effect of CGP-37157.

While several studies have investigated the toxic effects induced by \(\alpha\)-syn and Rot on neurons, including synaptic dysfunction, oxidative stress, and mitochondrial complex I deficiency, little is known on the mechanisms underlying the convergent detrimental effects induced by the concomitant application of \(\alpha\)-syn and Rot. Previous reports have demonstrated that in PC12 cells and in neurons of the substantia nigra, Rot raised intracellular Ca\(^{2+}\), leading to increased \(\alpha\)-syn aggregation.

Here, we presented electrophysiological evidence that in striatal rat slices, \(\alpha\)-syn plus Rot led to enhanced neurotoxic effects causing progressive irreversible loss of excitatory striatal transmission and electrical signals. This detrimental effect could be prevented by blocking mitochondrial NCX1, suggesting that NCX\(_{\text{mit}}\) could represent an important target for the control of acute synaptic dysfunction induced by the concomitant action of \(\alpha\)-syn and Rot. Growing evidence suggest that, in the presence of toxic stimulus, the mitochondrial Ca\(^{2+}\) uptake may induce apoptosis in a variety of pathological conditions. In particular, Ca\(^{2+}\) dysregulation has been previously reported in \(\alpha\)-synopathy models of PD. Accordingly, evidence from many studies suggest that \(\alpha\)-syn and Ca\(^{2+}\) may be related in several ways. For instance, it has been reported that \(\alpha\)-syn induces a reduction of \(\Delta\Psi\) and a disruption of electronic transport complex (ETC), thus accelerating the mitochondrial permeability transition pore (mPTP) opening. In addition, an increase in cytosolic Ca\(^{2+}\) levels may also occur since \(\alpha\)-syn may form plasma membrane pores, allowing extracellular Ca\(^{2+}\) to pass into the cytosol. This in turn may worsen mitochondrial function through the increased Ca\(^{2+}\) uptake. Moreover, Angelova et al. showed that the overexpression of intracellular \(\alpha\)-syn in neuroblastoma cells altered basal and depolarizing-stimulus-evoked Ca\(^{2+}\) signals and confirmed that \(\alpha\)-syn per se can induce a Ca\(^{2+}\) flux across neuronal membranes through pore formation. Several Ca\(^{2+}\) transporters are implicated in the ionic regulation, and between them NCXs (namely NCX1, NCX2, and NCX3) represent critical proteins contributing to Ca\(^{2+}\) homeostasis in the brain. Accordingly, the expression of all three NCX isoforms has been already reported in isolated mitochondria. Recently, the main role of plasma membrane and mitochondrial NCX1 in controlling energy metabolism in several cell types, including neurons and astrocytes, has been demonstrated. Interestingly, a metabolic stimulus, such as glutamate, could induce the reverse mode of NCXm, as a consequence of glutamate-induced Na\(^{+}\) influx through excitatory amino acid transporters. \(\alpha\)-Syn and Rot interact with Na\(^{+}\)/K\(^{+}\)-ATPase with a reduction of its ability to pump out Na\(^{+}\), thus leading to Na\(^{+}\) accumulation. Consequently, Ca\(^{2+}\) overload may occur. In line with these observations, it is possible to speculate that under our conditions, the Na\(^{+}\) influx and the disruption of ETC may contribute to \(\Delta\Psi\) perturbation, ultimately forcing the mitochondrial NCX1 to work on the reverse
mode and leading to Ca\(^{2+}\) increase. Our data showed that in SH-SY5Y cells, Ca\(^{2+}\) increase can be prevented by silencing of NCX1, mimicking the effect of CGP-37157 in striatal slices. An interesting study has already proposed that plasmalemmal NCX isoforms, in particular NCX2 and NCX3, contribute to mitochondrial Na\(^{+}/Ca\(^{2+}\)\) exchanger in human DAergic neurons acting downstream PINK1, a pathway implicated in a recessive form of PD, preventing neuronal death induced by mitochondrial Ca\(^{2+}\) accumulation\(^{20}\). Notably, the role of another mitochondrial Ca\(^{2+}\) antiporter, NCLX, has been reported\(^{51}\). Palty et al.\(^{17}\) and Luongo et al.\(^{18}\) demonstrated that in SH-SY5Y undifferentiated cells and transgenic mice, NCLX is an essential regulator for mitochondrial Ca\(^{2+}\) homeostasis. Nevertheless, the same authors showed that the pharmacological modulation of NCLX (using CGP-37157) did not fully inhibit mitochondrial Ca\(^{2+}\) efflux. Thus, NCLX may play an important role but its contribution is not sufficient to regulate mitochondrial Ca\(^{2+}\) levels. Therefore, as suggested by several evidences, it is reasonable to hypothesize that other transporters, including NCX1, play a critical role in controlling mitochondrial Ca\(^{2+}\) homeostasis\(^{19,21}\).

In line with our findings and existing literature, we can assert the relevance of mitochondria in the pathology of PD. The involvement of mitochondrial defects in PD pathology is also supported by pharmacological evidence showing deleterious effects of inhibitors of the mitochondrial electron transport chain, such as Rot, mPTP, or parquat\(^{22}\). Furthermore, our data confirmed that \(\alpha\)-syn has an important role in controlling neuronal mitochondrial dynamics, and in particular in regulating Ca\(^{2+}\) signals in animal models of PD as well as in PD patients\(^{52}\).

In conclusion, our study shows for the first time a critical interaction among \(\alpha\)-syn Rot-induced toxicity and mitochondrial NCX1, suggesting that NCX1 might represent a possible target for disease modifying therapy in PD.

Acknowledgements

This work was supported by the Ministry of Health (grant RF-2013–02356215) and by the Fresco Institute Network Research Program (FI-NRP), Fresco Network of Excellence Italy Sites (09.12.2016) to P.C.

Author details

1Neurological Clinic, Department of Medicine, University of Perugia, Santa Maria della Misericordia Hospital, via Gambuli, 1, 06132 Perugia, Italy.
2IRCCS Santa Lucia Foundation, Laboratory of Neurophysiology, via del Bosfo di Fiorano, 64, 00143 Rome, Italy.
3Department of Biomedical Sciences and Public Health, School of Medicine, University Politecnica delle Marche, viale Trento 10, 60126 Ancona, Italy.
4Department of Experimental Medicine, Section of Physiology and Biochemistry, University of Perugia, via Gambuli, 1, 06132 Perugia, Italy.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at https://doi.org/10.1038/s41419-018-1290-6.

Received: 20 August 2018 Revi ed: 14 November 2018 Accepted: 28 November 2018

Published online: 28 January 2019

References

1. Shulman, J. M., De Jager, P. L. & Feany, M. B. Parkinson’s disease: genetics and pathogenesis. Annu. Rev. Pathol. 6, 193–222 (2011).
2. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473 (1998).
3. Fuchs, J. et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 22, 1327–1334 (2008).
4. Miller, D. W. et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835–1838 (2004).
5. Guhathakurta, S., Bok, E., Evangelista, B. A. & Kim, Y. S. Deregression of alpha-synuclein in Parkinson’s disease: insight from epigenetic structure and transcriptional regulation of SNCA. Proc. Natl Acad. 114, 21–36 (2017).
6. Melli, R. Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. J. Park. Dis. 5, 217–227 (2015).
7. Tozzi, E. et al. Alpha-synuclein produces early behavioral alterations via striatal cholinergic synaptic dysfunction by interacting with GluN2D N-methyl-D-aspartate receptor subunit. Biol. Psychiatry 79, 402–414 (2016).
8. Diogenes, M. J. et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32, 11750–11762 (2012).
9. Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G. & Anandatheertha-varada, H. K. Mitochondrial import and accumulation of alpha-synuclein impairs complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 9089–9100 (2008).
10. Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S. & Seilhoe, D. J. Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca\(^{2+}\)-induced mitochondrial dysfunction. J. Biol. Chem. 289, 21400–21507 (2014).
11. Chofla, A. et al. Specific pesticide-dependent increase in alpha-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines, Toxicol. Sci. 133, 289–297 (2013).
12. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3, 1301–1306 (2000).
13. Bonsi, P. et al. Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies. Curr. Neuropharmacol. 4, 69–75 (2006).
14. Sherr, T. B. et al. Mechanism of toxicity in rotenone models of Parkinson’s disease. J. Neurosci. 23, 10765–10764 (2003).
15. Melachroinou, K. et al. Deregulation of calcium homeostasis mediates secreted alpha-synuclein-induced neurotoxicity. Neurobiol. Aging 34, 2853–2865 (2013).
16. Wang, X. J. & Xu, J. X. Possible involvement of Ca\(^{2+}\)-signaling in rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 376, 127–132 (2005).
17. Palty, R. et al. NCLX is an essential component of mitochondrial Na\(^{+}/Ca\(^{2+}\) exchange. Proc. Natl Acad. Sci. USA 107, 436–441 (2010).
18. Luongo, T. S. et al. The mitochondrial Na\(^{+}\)/Ca\(^{2+}\) exchanger is essential for Ca\(^{2+}\) homeostasis and viability. Nature 545, 93–97 (2017).
19. Gobbi, P. et al. Mitochondrial localization of Na\(^{+}/Ca\(^{2+}\) exchangers NCX1-3 in neurons and astrocytes of adult rat brain in situ. J. Physiol. 565, 556–565 (2004).
20. Wood-Kaczmar, A., Deas, E., Wood, N. W. & Abramov, A. Y. The role of the mitochondrial NCX in the mechanism of neurodegeneration in Parkinson’s disease. Adv. Exp. Med. Biol. 691, 241–249 (2013).
21. Cali, T., Ottolini, D. & Brini, M. Calcium signaling in Parkinson’s disease. Cell. Tissue Res. 357, 439–454 (2014).
22. Liu, T. C. et al. The mitochondrial Na\(^{+}/Ca\(^{2+}\) exchanger is necessary but not sufficient for Ca\(^{2+}\) homeostasis and viability. Adv. Exp. Med. Biol. 1072, 281–285 (2018).
23. Philpson, K. D. & Nicoll, D. A. Sodium-calcium exchange: a molecular perspective. Annu. Rev. Physiol. 62, 111–133 (2000).
24. Blaustein, M. P. & Lederer, W. J. Sodium/calcium exchange: its physiological implications. Physiol. Rev. 79, 763–854 (1999).
25. Papa, M. et al. Differential expression of the Na(+)-Ca2+ exchanger transcripts and proteins in rat brain regions. J. Comp. Neurol. 461, 31–48 (2003).
26. Minelli, A. et al. Cellular and subcellular localization of Na(+)-Ca2+ exchanger protein isoforms, NCX1, NCX2, and NCX3 in cerebral cortex and hippocampus of adult rat. Cell Calcium 41, 221–234 (2007).
27. Ago, Y. et al. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPP+-induced model of Parkinson’s disease. Neuropharmacology 61, 1441–1451 (2011).
28. Mazzocchetti, P. et al. Lacosamide protects striatal and hippocampal neurons from in vitro ischemia without altering physiological synaptic plasticity. Neur.opharmacology 135, 424–430 (2018).
29. Kita, S. & Iwamoto, T. Inhibitory mechanism of SN-6, a novel benzoyloxyphenyl Na+/Ca2+ exchange inhibitor. Ann. N.Y. Acad. Sci. 1099, 529–533 (2007).
30. Sherkhane, P. & Kapfhammer, J. P. Chronic pharmacological blockade of the Na(+)/Ca2(+) exchanger modulates the growth and development of the Purkinje cell dendritic arbor in mouse cerebellar slice cultures. Eur. J. Neurosci. 46, 2106–2120 (2017).
31. Magi, S. et al. Physical and functional interaction of NCX1 and EAAC1 transporters leading to glutamate-enhanced ATP production in brain mitochondria. PLoS ONE 7, e34015 (2012).
32. Filograna, R. et al. Analysis of the catecholaminergic phenotype in human SH-SY5Y and BE(2)-M17 neuroblastoma cell lines upon differentiation. PLoS ONE 10, e0136769 (2015).
33. Ronsisvalle, N. et al. CHF5074 protects SH-SY5Y human neuronal-like cells from ischemic injury. Acta Neurochir. Suppl. 118, 65–70 (2013).
34. Castaldo, P. et al. Role of the mitochondrial sodium/calcium exchanger in neuronal physiology and in the pathogenesis of neurological diseases. Prog. Neurobiol. 87, 58–79 (2009).
35. Magi, S. et al. Gram-negative endotoxin lipopolysaccharide induces cardiac hypertrophy: detrimental role of Na(+)-Ca2(+) exchanger. Eur. J. Pharmacol. 746, 31–40 (2015).
36. Reeves, J. P. & Condrescu, M. Allosteric activation of sodium-calcium exchange inhibitors. Front. Physiol. 9, 295 (2018).
37. Yuan, Y. H. et al. The molecular mechanism of rotenone-induced alpha-synuclein aggregation: emphasizing the role of the calcium/GSK3beta pathway. Toxicol. Lett. 233, 163–171 (2015).
38. Ghiglieri, V., Calabrese, V. & Calabresi, P. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration. Front. Neurol. 9, 205 (2018).
39. Costa, C. et al. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J. Neurosci. 38, 8040–8052 (2018).
40. Mazzocchetti, P. et al. Na(+)/Ca2(+) exchanger transcripts and proteins in rat brain regions. J. Neurosci. 25, 10993–10998 (2005).
41. Persson, A. K. et al. Sodium channels contribute to degeneration of dorsal root ganglion neurites induced by mitochondrial dysfunction in an in vitro model of axonal injury. J. Neurosci. 33, 19250–19261 (2013).
42. Ruiz, A., Alberdi, E. & Matute, C. CGP37157, an inhibitor of the mitochondrial Na(+)/Ca2(+) exchange, protects neurons from excitotoxicity by blocking voltage-gated Ca2+ channels. Cell Death Dis. 5, e1156 (2014).
43. Pozo devoto, B. M. & Falzone, T. L. Mitochondrial dynamics in Parkinson’s disease: a role for alpha-synuclein? Dis. Model Mech. 10, 1075–1087 (2017).